Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

CYTO

Altamira Therapeutics Ltd

Apr 26 • 01:37PM ET

1.60

Dollar change -0.00
Percentage change -0.31	%

Healthcare • Biotechnology • Bermuda • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	0.06%	Shs Outstand	2.24M	Perf Week	12.80%
Market Cap	3.57M	Forward P/E	-	EPS next Y	-3.03	Insider Trans	0.00%	Shs Float	2.24M	Perf Month	-32.13%
Income	-	PEG	-	EPS next Q	-	Inst Own	0.34%	Short Float	3.87%	Perf Quarter	-20.25%
Sales	-	P/S	-	EPS this Y	73.65%	Inst Trans	19.62%	Short Ratio	0.07	Perf Half Y	-52.30%
Book/sh	-0.26	P/B	-	EPS next Y	29.05%	ROA	-	Short Interest	0.09M	Perf Year	-92.33%
Cash/sh	0.03	P/C	59.55	EPS next 5Y	-	ROE	-	52W Range	1.35 - 28.40	Perf YTD	-54.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	50.52%	ROI	-	52W High	-94.38%	Beta	2.55
Dividend TTM	-	Quick Ratio	0.27	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	18.15%	ATR (14)	0.21
Dividend Ex-Date	-	Current Ratio	0.32	EPS Y/Y TTM	5.52%	Oper. Margin	-1363.43%	RSI (14)	44.63	Volatility	13.58% 11.96%
Employees	12	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	287.34
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	87.98%	Payout	-	Rel Volume	0.07	Prev Close	1.60
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	Apr 10 BMO	Avg Volume	1.19M	Price	1.60
SMA20	-9.74%	SMA50	-13.89%	SMA200	-61.31%	Trades		Volume	55,204	Change	-0.31%

Apr-24-24 08:47AM	Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal (GlobeNewswire) -8.86%
Apr-17-24 08:00AM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024 (GlobeNewswire) -9.20%
Apr-15-24 08:00AM	Diamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO) (GlobeNewswire) -9.29%
Apr-12-24 08:20AM	Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-10-24 08:00AM	Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results (GlobeNewswire) +7.53%
08:45AM	Loading…
Apr-04-24 08:45AM	Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 (GlobeNewswire) +7.73%
Mar-25-24 08:47AM	Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines (GlobeNewswire) +35.84%
Feb-07-24 08:47AM	Altamira Therapeutics' Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal (GlobeNewswire)
Jan-24-24 08:47AM	Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment (GlobeNewswire) +8.57%
Jan-08-24 08:47AM	Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit (GlobeNewswire)
Dec-29-23 08:47AM	Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +7.41%
Dec-14-23 05:51AM	CYTO Stock Earnings: Altamira Therapeutics Reported Results for H1 2023 (InvestorPlace) -13.97%
Dec-11-23 08:00AM	Altamira Therapeutics Provides Investor and Business Update (GlobeNewswire) -53.79%
Dec-05-23 12:54PM	Altamira Therapeutics to Host Investor & Business Update Call on December 11th (GlobeNewswire) +18.92%
Nov-29-23 10:20AM	Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement (GlobeNewswire) +180.22%
08:48AM	Loading…
Nov-27-23 08:48AM	Why Is Altamira Therapeutics (CYTO) Stock Down 8% Today? (InvestorPlace) -21.77%
Nov-17-23 02:45PM	Why Is Altamira Therapeutics (CYTO) Stock Up 160% Today? (InvestorPlace) +180.28%
09:04AM	Altamira Therapeutics Announces Partial Spin-Off of Bentrio Business (GlobeNewswire)
Nov-10-23 08:47AM	Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine (GlobeNewswire) -11.25%
Sep-14-23 08:47AM	Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis (GlobeNewswire) -5.72%
Sep-12-23 07:30AM	Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results (GlobeNewswire) -6.03%
Sep-06-23 08:47AM	Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th (GlobeNewswire)
Aug-23-23 08:47AM	Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 (GlobeNewswire)
Jul-20-23 08:47AM	Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia (GlobeNewswire)
Jul-17-23 08:47AM	Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal (GlobeNewswire)
Jul-06-23 08:00AM	Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering (ACCESSWIRE) -8.81%
Jul-05-23 08:47AM	Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration (GlobeNewswire) -6.70%
Jun-15-23 08:47AM	Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome (ACCESSWIRE)
May-31-23 04:30PM	Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets (ACCESSWIRE)
May-24-23 08:47AM	Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis (ACCESSWIRE)
07:30AM	Loading…
May-16-23 07:30AM	Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results (ACCESSWIRE)
May-12-23 08:47AM	Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023 (ACCESSWIRE)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE) -7.89%
May-01-23 08:47AM	Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11 (ACCESSWIRE) -11.93%
Apr-12-23 09:30AM	Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal (ACCESSWIRE) +59.09%
Apr-11-23 09:58AM	Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles (ACCESSWIRE) -36.23%
Apr-10-23 08:47AM	Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo (ACCESSWIRE) +12.50%
Mar-22-23 08:47AM	Altamira Therapeutics SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model (GlobeNewswire)
Mar-15-23 08:47AM	Altamira Therapeutics SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model (ACCESSWIRE)
Mar-03-23 08:47AM	Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties (ACCESSWIRE) +5.51%
Feb-27-23 08:47AM	Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment (GlobeNewswire)
Feb-14-23 08:47AM	Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meeting (ACCESSWIRE)
Feb-07-23 08:47AM	Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023 (ACCESSWIRE)
Jan-27-23 08:47AM	Altamira Therapeutics Provides Business Update (GlobeNewswire) -12.89%
Jan-24-23 08:17AM	Altamira Therapeutics Provides Update on Clinical Trials with Bentrio (GlobeNewswire) -29.12%
Jan-10-23 08:47AM	Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th (GlobeNewswire)
Dec-19-22 08:47AM	Altamira Therapeutics Provides Year-End 2022 Business Update (GlobeNewswire) -14.16%
Dec-02-22 08:47AM	Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia (ACCESSWIRE)
Nov-30-22 08:47AM	Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results (GlobeNewswire) -6.77%
08:07AM	Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma (GlobeNewswire)
Nov-22-22 08:47AM	In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability (ACCESSWIRE) +6.27%
Nov-10-22 08:47AM	Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event (GlobeNewswire)
Nov-09-22 08:47AM	Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement (GlobeNewswire) -9.52%
Nov-08-22 08:47AM	Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamiras Bentrio under Controlled Grass Pollen Exposure (GlobeNewswire)
Oct-24-22 08:47AM	Altamira Therapeutics Announces Reverse Stock Split (GlobeNewswire) -24.96%
Oct-21-22 08:47AM	Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets (GlobeNewswire) +58.64%
Oct-13-22 08:47AM	Altamira Therapeutics to Participate at RNA Leaders USA Congress (GlobeNewswire)
Oct-03-22 08:47AM	Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia (GlobeNewswire) -7.42%
Sep-27-22 08:47AM	Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis (GlobeNewswire) +7.72%
Sep-13-22 08:47AM	Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19 (GlobeNewswire)
Sep-08-22 08:57AM	Altamira Therapeutics to Host Investor Call on September 14th (GlobeNewswire) -9.31%
07:17AM	Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit (GlobeNewswire)
Aug-30-22 09:24AM	Altamira Therapeutics Provides Business Update (GlobeNewswire) -5.94%
Aug-03-22 12:15PM	Altamira Therapeutics CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic Transformation (GlobeNewswire)
Aug-01-22 08:47AM	Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19 (GlobeNewswire) -5.55%
Jul-28-22 08:47AM	Altamira Therapeutics Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal (GlobeNewswire) +7.14%
Jul-25-22 08:47AM	Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint (GlobeNewswire)
Jul-19-22 08:47AM	Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy (GlobeNewswire) +17.11%
Jul-12-22 08:47AM	Altamira Therapeutics RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal (ACCESSWIRE) +11.32%
Jun-29-22 07:30AM	Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan (ACCESSWIRE)
Jun-27-22 08:30AM	Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis (ACCESSWIRE) +11.57%
Jun-23-22 08:47AM	Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19 (ACCESSWIRE)
Jun-13-22 08:47AM	Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo (ACCESSWIRE) -5.85%
Jun-09-22 05:25PM	Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements (ACCESSWIRE)
Jun-08-22 08:47AM	Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray (ACCESSWIRE)
May-31-22 08:47AM	Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia (ACCESSWIRE)
May-23-22 08:47AM	Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray (ACCESSWIRE)
May-20-22 09:00AM	Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study (ACCESSWIRE)
May-19-22 09:00AM	Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference (ACCESSWIRE) +5.68%
May-18-22 08:47AM	Altamira Therapeutics Issues Shareholder Letter (ACCESSWIRE)
May-05-22 08:47AM	Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia (ACCESSWIRE)
Apr-19-22 09:00AM	Altamira Reaches COVAMID Trial Enrollment Midpoint for Bentrio in Acute COVID-19 (ACCESSWIRE) +6.37%
Apr-12-22 07:30AM	Altamira Therapeutics Provides Business Update and Reports Second Half and Full Year 2021 Financial Results (ACCESSWIRE) -31.33%
Apr-11-22 08:47AM	Altamira Therapeutics Announces Peer-Reviewed Publication on Positive in vitro Data with its Bentrio(TM) Drug-Free Nasal Spray Against SARS-CoV-2 Delta Variant (ACCESSWIRE) +55.14%
Apr-04-22 08:47AM	Altamira Therapeutics Sets Full Year 2021 Earnings Call for Tuesday, April 12, 2022, 8:00 a.m. ET (ACCESSWIRE)
Mar-15-22 09:00AM	Altamira Therapeutics Completes Patient Enrollment in House Dust Mite Allergy Trial with Bentrio (ACCESSWIRE)
Mar-11-22 09:00AM	Altamira Therapeutics Reports Positive In Vitro Efficacy Data for Bentrio Nasal Spray in Protecting Against Sars-CoV-2 Omicron Variant (ACCESSWIRE) +36.70%
Mar-09-22 09:00AM	Altamira Therapeutics Receives Approval to Commence Clinical Trial Evaluating Bentrio in the Treatment of COVID-19 (ACCESSWIRE)
Mar-04-22 09:15AM	Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets (ACCESSWIRE) -10.99%
Feb-14-22 09:00AM	Altamira Therapeutics Completes Final Patient Enrollment in Phase 2 'TRAVERS' Clinical Trial of AM-125 for the Treatment of Acute Vertigo (ACCESSWIRE)
Feb-09-22 09:00AM	Altamira Therapeutics and Wellesta Expand Bentrio Marketing and Distribution Agreement to Include Two Additional Markets (ACCESSWIRE Test RSS)
Feb-07-22 09:00AM	Altamira Therapeutics and Avernus Pharma Collaborate for Marketing and Distribution of Bentrio in Gulf Countries (ACCESSWIRE)
Feb-04-22 09:25AM	Altamira Therapeutics Establishes OTC Consumer Health Business Unit (ACCESSWIRE) +6.72%
Jan-21-22 09:00AM	Altamira Therapeutics Announces Approval of Bentrio Nasal Spray in Malaysia (ACCESSWIRE) -8.22%
Jan-13-22 09:00AM	Altamira Therapeutics Provides Update on RNA Therapeutics Program (ACCESSWIRE) -9.77%
Jan-05-22 09:00AM	Altamira Therapeutics to Participate in the H.C. Wainwright BioConnect Virtual Conference (ACCESSWIRE) -5.91%
Dec-29-21 09:15AM	Altamira Therapeutics Provides Update on Bentrio Program (ACCESSWIRE) +35.76%
Dec-16-21 09:00AM	Altamira Therapeutics Announces Randomization of First Patients in Bentrio Trial in House Dust Mite Allergy (ACCESSWIRE)
Dec-01-21 09:00AM	Altamira Therapeutics Announces Randomization of First Patient in Bentrio Trial in Seasonal Allergic Rhinitis (ACCESSWIRE) -7.91%
Nov-15-21 09:00AM	Altamira Therapeutics Announces Poster Presentations at AHA Scientific Sessions 2021 (ACCESSWIRE)

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CYTO

Altamira Therapeutics Ltd

Upgrade your FINVIZ experience